We ensure our quality and safety based on data collection

Kingenic clinical studies programme is designed to establish safety and efficacy of the products we develop.

Clinical trials are conducted to collect data regarding the safety and efficacy of new drug development. There are several steps and stages of approval in the clinical trials process before a drug or device can be sold in the consumer market, if ever. Our R&D team works with a wide range of academic institutions, research bodies, and regulators within India and across the world.

Phases 1

At this point, the compound is tested mainly on a limited number of healthy subjects, who may receive compensation and are under strict medical supervision. The compound is tested over a short period of time. The purpose is to evaluate the product’s safety, how it evolves within the body, the tolerance threshold and adverse events.

Phases 1

Testing involves larger groups of patients. The purpose is to test the product’s efficacy and determine optimal dosage regimen. These studies are usually comparative: one of two groups of patients is administered the product whereas the other group is given a placebo.

Phase 3

Testing involves large number of patients, with the purpose of comparing the therapeutic efficacy of the compound to a reference treatment or to a placebo. Such studies are very frequently multicentric. Generally, neither the patient, nor the medical professions are aware of what each patient is being treated with; this is to avoid any bias or prejudiced opinion on either side regarding efficacy or adverse events. Once these 3 phases have been successfully completed, the resulting data, together with the results of preclinical testing, are collected to compose a registration file that will be submitted to public health authorities for license to market.

Phase 4

Trials do not cease once the pharmaceutical has been put on sale; they continue throughout its marketing life. Trials called Phase 4, are carried out after approval in conditions close to those of usual medical care. Specific targets at this point are to detect possible rare undesirable side effects which had escaped attention in the previous phases and to define conditions of use for certain groups of at-risk patients. During this phase, drug interactions can be listed and new forms and therapeutic indication extensions can be developed.